6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY, UT
News, Legal Opinion
Investor Presentation
Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients
REPORTS Second QUARTER 2025 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS
Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings
Other Events
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Statement of Changes in Beneficial Ownership
Statement of Changes in Beneficial Ownership
Specialized Disclosure Report
Correspondence